Venous Thromboembolism (VTE) Prophylaxis With REGN7508 and REGN9933 in Adult and Adolescent Participants With a Peripherally Inserted Central Catheter (PICC)

← catalyst calendar

NCT07697599 · readout in 1,041 d

Sponsored by Regeneron Pharmaceuticals (industry) · REGN — their whole pipeline →.

Phase

Phase 3

Status

Not yet recruiting

Study type

Interventional

Design

Randomized · Quadruple · Treatment

Enrollment

1,908estimated

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2026-08-20

estimated

When the study began enrolling

Primary completion

2029-06-25

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2029-09-21

estimated

The whole study's end, after follow-up

First posted

2026-07-13

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-07-13

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Venous Thromboembolism (VTE)

Interventions

Drug: REGN7508 — also filed as cenvacibart
Drug: REGN9933 — also filed as amrecibart
Drug: Placebo

Primary outcomes

what the primary-completion date above is the date OF

Time-to-first event of centrally adjudicated VTE [symptomatic VTE or incidental VTE or asymptomatic VTE]

measured Approximately 6 months

Time-to-first event of centrally adjudicated International Society on Thrombosis and Haemostasis (ISTH)-defined major bleeding or Clinically Relevant Non-Major (CRNM) bleeding

measured Approximately 6 months

Permalink · REGN's whole pipeline · Catalyst calendar · Every registered study · What changed